IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients

Journal of Viral Hepatitis

Volumn 20, Issue 5, 2013, Pages 358-366

  Jimenez Sousa M A ^a   Berenguer, J ^b   Rallon N ^c   Guzman Fulgencio M ^a   Lopez J C ^b   Soriano, V ^c   Fernandez Rodriguez A ^a   Cosin J ^b   Restrepo, C ^c   Garcia Alvarez M ^a   Miralles, P ^b   Benito, J M ^c   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

chronic hepatitis C; HIV; IL28B; IL28RA; interferon; polymorphism

Indexed keywords

INTERLEUKIN 28; INTERLEUKIN 28 RECEPTOR ALPHA; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ALLELE; ARTICLE; CLINICAL OBSERVATION; DECISION TREE; FEMALE; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CYTOKINE; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT FAILURE;

EID: 84876138324     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12041     Document Type: Article

References (36)

1. Gonzalez-Garcia JJ, Mahillo B, Hernandez S, et al,. Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study. Enferm Infecc Microbiol Clin 2005; 23 (6): 340-348. (Pubitemid 41020545)
2. Kim AY, Chung RT,. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 2009; 137 (3): 795-814.
3. Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, et al,. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011; 25 (7): 899-904.
4. Soriano V, Puoti M, Sulkowski M, et al,. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21 (9): 1073-1089. (Pubitemid 46763278)
5. Tural C, Galeras JA, Planas R, et al,. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther 2008; 13 (8): 1047-1055.
6. Pol S, Soriano V,. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008; 47 (1): 94-101. (Pubitemid 351920593)
7. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
8. Sulkowski M,. Exploring the possibility of an interferon-free treatment regimen for hepatitis C virus infection. Gastroenterol Hepatol 2011; 7 (3): 185-187.
9. Laguno M, Larrousse M, Murillas J, et al,. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr 2007; 44 (2): 174-178. (Pubitemid 46292220)
10. de Castellarnau M, Aparicio E, Parera M, et al,. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS ONE 2012; 7 (2): e31016.
11. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
12. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10): 1100-1104.
13. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10): 1105-1109.
14. Levy DE, Marie IJ, Durbin JE,. Induction and Function of Type I and III Interferon in Response to Viral Infection. Curr Opin Virol 2011; 1 (6): 476-486.
15. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R,. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81 (14): 7749-7758. (Pubitemid 47047861)
16. Yang L, Luo Y, Wei J, He S,. Integrative genomic analyses on IL28RA, the common receptor of interferon-lambda1, -lambda2 and -lambda3. Int J Mol Med 2010; 25 (5): 807-812.
17. Soriano V, Poveda E, Vispo E, Labarga P, Rallon N, Barreiro P,. Pharmacogenetics of hepatitis C. J Antimicrob Chemother 2012; 67 (3): 523-529.
18. Pineda JA, Caruz A, Di Lello FA, et al,. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 2011; 25 (11): 1415-1420.
19. Medrano J, Neukam K, Rallon N, et al,. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51 (10): 1209-1216.
20. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289-293. (Pubitemid 26260021)
21. Castera L, Vergniol J, Foucher J, et al,. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343-350. (Pubitemid 40439195)
22. Wigginton JE, Cutler DJ, Abecasis GR,. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76 (5): 887-893. (Pubitemid 40563110)
23. Barrett JC, Fry B, Maller J, Daly MJ,. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 (2): 263-265. (Pubitemid 40202029)
24. Purcell S, Neale B, Todd-Brown K, et al,. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81 (3): 559-575. (Pubitemid 47330214)
25. Afdhal NH, McHutchison JG, Zeuzem S, et al,. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2010; 53 (1): 336-345.
26. Holmes JA, Desmond PV, Thompson AJ,. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection. Clin Liver Dis 2011; 15 (3): 497-513.
27. Labarga P, Barreiro P, Mira JA, et al,. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse. AIDS 2011; 25 (8): 1131-1133.
28. Rivero-Juarez A, Camacho Espejo A, Perez-Camacho I, et al,. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother 2012; 67 (1): 202-205.
29. Thompson AJ, Muir AJ, Sulkowski MS, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1): 120-129. e18.
30. Stattermayer AF, Stauber R, Hofer H, et al,. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9 (4): 344-350. e2.
31. Lopez de Lapuente A, Alloza I, Goertsches R, et al,. Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. J Neuroimmunol 2012; 245: 98-101.
32. Strange A, Capon F, Spencer CC, et al,. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42 (11): 985-990.
33. Cui Q, Zhang YX, Su J, et al,. Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect Genet Evol 2011; 11 (7): 1682-1689.
34. Rao HY, Sun DG, Jiang D, et al,. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepatitis 2012; 19 (3): 173-181.
35. Aparicio E, Parera M, Franco S, et al,. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE 2010; 5 (10): e13771.
36. Dill MT, Duong FH, Vogt JE, et al,. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140 (3): 1021-1031.